Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4787073 | 0.93 | CNR2 (0.49) | CNR2KCNH2CYP1A2CYP2C9 | |
| SCHEMBL4786019 | 0.90 | CNR2 (0.57) | CNR2KCNH2CYP1A2CYP2C9 | |
| SCHEMBL4788220 | 0.85 | — | — | |
| SCHEMBL4785234 | 0.85 | CNR2 (0.55) | CNR2CYP1A2CYP2C9 | |
| SCHEMBL4786485 | 0.83 | CNR2 (0.59) | CNR2 | |
| SCHEMBL4786593 | 0.82 | CNR2 (0.49) | CNR2 | |
| SCHEMBL4789933 | 0.82 | CNR2 (0.60) | CNR2 | |
| SCHEMBL4787554 | 0.81 | — | — | |
| SCHEMBL4784158 | 0.81 | CNR2 (0.54) | CNR2 | |
| SCHEMBL4745185 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207705-A1 | Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-08-28 | — | — | US | claimed |
| WO-2008105607-A1 | HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008105607-A1 | HETEROARYL-IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207705-A1 | Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-08-28 | — | — | US | disclosed |
| US-20080207705-A1 | Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-08-28 | — | — | US | disclosed |
| US-20080207705-A1 | Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207705-A1 | Heteroaryl-Imidazole Derivatives as Cannabinoid CB1 Receptor Antagonists | CNR2, CNR1, GPR119 | CNR2 1/4885KCNH2 1076/4885CYP1A2 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.